Subsidy for CGRP inhibitor ‘a milestone’
Thousands of patients are expected to benefit, a neurologist says
The first calcitonin gene-related peptide (CGRP) inhibitor to be PBS listed will prompt reassessment for many patients severely affected by migraine, a leading neurologist says.
Associate Professor Richard Stark, from the Alfred Hospital in Melbourne, said the listing of galcanezumab (Emgality, Eli Lilly) from 1 June for patients with chronic migraine was a “tremendous milestone”.
